Diabetology Ltd

Diabetology Ltd is a biopharmaceutical company founded in 2002 and registered in Saint Helier, Jersey.[1] The company develops oral drugs for the treatment of diabetes mellitus.[2][3]

"Diabetology" redirects here. For the scientific discipline, see Diabetes mellitus.
Diabetology Limited
TypePrivate
IndustryBiotechnology
FoundedJersey (November 13, 2002 (2002-11-13))
HeadquartersSaint Helier, Jersey (registered office)
Key people
Roger New (CSO)
Glen Travers
Products2 in clinical development and 3 in pre-clinical development
Websitewww.diabetology.co.uk

Products

Currently, the company doesn't have a marketed product, though its pipeline includes one drug that has recently completed phase II clinical development, one in phase II clinical development, and three in pre-clinical development.[4]

Drug Phase Action
Capsulin OAD[3] Phase II clinical trial completed Oral insulin for diabetes mellitus type 2
Capsulin IR Phase II clinical trial Oral insulin for diabetes mellitus type 1
Combulin Pre-clinical development Oral combination of insulin and insulin sensitizing agents for diabetes mellitus type 2
Oral GLP-1 Pre-clinical development Improves glycaemic and diet control in diabetes mellitus type 2
Oral C-Petdide Pre-clinical development Reduces diabetic complications

References
  1. "Entity Detail". www.jerseyfsc.org. Retrieved 1 August 2018.
  2. "'Insulin pill' hope for diabetes". 22 June 2007. Retrieved 1 August 2018 – via news.bbc.co.uk.
  3. Taylor, Phil (17 February 2016). "Oral biologics delivery still elusive". Retrieved 4 February 2018.
  4. "Diabetology Ltd - Clinical pipeline". Archived from the original on 14 August 2016. Retrieved 1 August 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.